Ruthenium complex exerts antineoplastic effects that are mediated by oxidative stress without inducing toxicity in Walker-256 tumor-bearing rats

Free Radical Biology and Medicine

Volumn 110, Issue , 2017, Pages 228-239

  Alves de Souza, Carlos Eduardo ^a   Alves de Souza, Helen de Morais ^a   Stipp, Maria Carolina ^a   Corso, Claudia Rita ^a   Galindo, Claudia Martins ^a   Cardoso, Carolina Riverin ^b   Dittrich, Rosangela Locatelli ^a   de Souza Ramos, Edneia Amancio ^a   Klassen, Giseli ^a   Carlos, Rose Maria ^b   Correia Cadena, Sílvia Maria Suter ^a   Acco, Alexandra ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

Author keywords

Oxidative stress; Rats; RuphenImH; Ruthenium; Tumor; Walker 256

Indexed keywords

1,10 PHENANTHROLINE; ANTINEOPLASTIC AGENT; CATALASE; CISPLATIN; GLUTATHIONE; GLUTATHIONE TRANSFERASE; IMIDAZOLE DERIVATIVE; RUTHENIUM COMPLEX; SUPEROXIDE DISMUTASE; BAX PROTEIN, RAT; BCL2 PROTEIN, RAT; CASP3 PROTEIN, RAT; CASPASE 3; COORDINATION COMPOUND; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RUTHENIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BIOCHEMISTRY; CELL DEATH; CELL RESPIRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; GENE EXPRESSION; HISTOLOGY; MALE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; WALKER CARCINOMA; WISTAR RAT; AGONISTS; ANIMAL; CELL SURVIVAL; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NECROSIS; PATHOLOGY; PRECLINICAL STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; SYNTHESIS; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA 256, WALKER; CASPASE 3; CELL RESPIRATION; CELL SURVIVAL; COORDINATION COMPLEXES; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; INJECTIONS, SUBCUTANEOUS; MALE; NECROSIS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RUTHENIUM; TUMOR BURDEN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85021194327     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2017.06.011     Document Type: Article

References (78)

1. Qu, K., Lin, T., Wei, J., Meng, F., Wang, Z., Huang, Z., Wan, Y., Song, S., Liu, S., Chang, H., Dong, Y., Liu, C., Cisplatin induces cell cycle arrest and senescence via upregulating P53 and P21 expression in HepG2 cells. J. South. Med. Univ. 33 (2013), 1253–1259.
2. Zhao, J.L., Zhao, J., Jiao, H., Synergistic growth-suppressive effects of quercetin and cisplatin on HepG2 human hepatocellular carcinoma cells. Appl. Biochem. Biotechnol. 172 (2014), 784–791.
3. Saleh, S., El-Demerdash, E., Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic. Clin. Pharmacol. Toxicol. 97 (2005), 91–97.
4. Im, G.J., Chang, J., Lee, S., Choi, J., Jung, H.H., Lee, H.M., Ryu, S.H., Park, S.K., Kim, J.H., Kim, H.J., Protective role of edaravone against cisplatin-induced ototoxicity in an auditory cell line. Hear. Res. 330 (2015), 113–118.
5. Zhang, C.X., Lippard, S.J., New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol. 7 (2003), 481–489.
6. Liu, H.K., Berners-Price, S.J., Wang, F.Y., Parkinson, J.A., Xu, J., Bella, J., Sadler, P.J., Diversity in G-selective DNA binding modes for an organometallic ruthenium arene complex. Angew. Chem. Int. 45 (2006), 8153–8156.
7. Li, L.L., Cao, W.Q., Zheng, W.J., Fan, C.D., Chen, T.F., Ruthenium complexes containing 2,6-bis(benzimidazolyl)pyridine derivatives induce cancer cell apoptosis by triggering DNA damage-mediated p53 phosphorylation. Dalton Trans. 41 (2012), 12766–12772.
8. Galanski, M., Arion, V.B., Jakupec, M.A., Keppler, B.K., Recent developments in the field of tumor-inhibiting metal complexes. Curr. Pharm. Des. 9 (2003), 2078–2089.
9. Levina, A., Mitra, A., Lay, P.A., Recent developments in ruthenium anticancer drugs. Metallomics 1 (2009), 458–470.
10. Rademaker-Lakhai, J.M., Van Den Bongard, D., Pluim, D., Beijnen, J.H., Schellens, J.H.M., A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole tetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res. 11 (2004), 3717–3727.
11. Alessio, E., Mestroni, G., Bergamo, A., Sava, G., Ruthenium antimetastatic agents. Curr. Top. Med. Chem. 4 (2004), 1525–1535.
12. Heffeter, P., Bock, K., Atil, B., Hoda, M.A.R., Korner, W., Bartel, C., Jungwirth, U., Keppler, B.K., Micksche, M., Berger, W., Koellensperger, G., Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J. Biol. Inorg. Chem. 15 (2010), 737–748.
13. Groessl, M., Hartinger, C.G., Dyson, P.J., Keppler, B.K., CZE− ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. J. Inorg. Biochem. 102 (2008), 1060–1065.
14. Groessl, M., Tsybin, Y.O., Hartinger, C.G., Keppler, B.K., Dyson, P.J., Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry. J. Biol. Inorg. Chem. 15 (2010), 677–688.
15. Groessl, M., Zava, O., Dyson, P.J., Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin. Metallomics 3 (2011), 591–599.
16. Sava, G., Alessio, E., Bergamo, A., Mestroni, G. Sulfoxide ruthenium complex: non toxic tools for the selective treatmente of solid tumor metastases. In: Metallopharmaceuticals I – Topics in Biological Inorganic Chemistry, Elsevier, 1999, 1, pp. 143–169.
17. Hartinger, C.G., Zorbas-Seifried, S., Jakupec, M., Kynast, B., Zorbas, H., Keppler, B.K., From bench to beside-preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole) ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem. 100 (2006), 891–904.
18. Pongratz, M., Schluga, P., Jakupec, M.A., Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. J. Anal. At. Spectrom. 19 (2004), 46–51.
19. Millis, K.K., Weaver, K.H., Rabenstein, D.L., Oxidation/reduction potential of glutathione. J. Org. Chem. 58 (1993), 4144–4146.
20. Jakupec, M.A., Reisner, E., Eichinger, A., Pongratz, M., Arion, V.B., Galanski, M., Hartinger, C.G., Keppler, B.K., Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. J. Med. Chem. 48 (2005), 2831–2837.
21. Reisner, E., Arion, V.B., da Silva, M.F.C.G., Lichtenecker, R., Eichinger, A., Keppler, B.K., Kukushkin, V.Y., Pombeiro, A.J.L., Tuning of redox potentials for the design of ruthenium anticancer drugs - an electrochemical study of [trans-RuCl4L(DMSO)]− and [trans-RuCl4L2]− complexes, where L = imidazole, 1,2,4-triazole, indazole. Inorg. Chem. 43 (2004), 7083–7093.
22. Reisner, E., Arion, V.B., Eichinger, A., Kandler, N., Giester, G., Pombeiro, A.J.L., Keppler, B.K., Tuning of redox properties for the design of ruthenium anticancer drugs: part 2. Syntheses, crystal structures, and electrochemistry of potentially antitumor [RuIII/IICl6-n(azole)n]z (n = 3, 4, 6) complexes. Inorg. Chem. 44 (2005), 6704–6716.
23. Santos, R.L.S.R., Van Eldik, R., de Oliveira Silva, D., Kinetic and mechanistic studies on reactions of diruthenium(II,III) with biologically relevant reducing agents. Dalton Trans. 42 (2013), 16796–16805.
24. Schluga, P., Hartinger, C.G., Egger, A., Reisner, E., Galanski, M., Jakupec, M.A., Keppler, B.K., Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans. 14 (2006), 1796–1802.
25. 2O. Inorg. Chem. 35 (1996), 4896–4903.
26. Hartmann, M., Lipponer, K.G., Keppler, B.K., Imidazole release from the antitumor-active ruthenium complex imidazolium transtetrachlorobis(imidazole) ruthenate(III) by biologically occurring nucleophiles. Inorg. Chim. Acta 267 (1998), 137–141.
27. 2+ to DNA by glutathione: reduction, autoxidation, coordination, and decomposition. J. Am. Chem. Soc. 121 (1999), 8523–8532.
28. Warburg, O., On the origin of cancer cells. Science 123 (1956), 309–314.
29. Wallace, D.C., Mitochondria and cancer. Nat. Rev. Cancer 12 (2012), 685–698.
30. Chan, D.C., Fusion and fission: interlinked processes critical for mitochondrial health. Annu. Rev. Genet. 46 (2012), 265–287.
31. Kowaltowski, A.J., Souza-Pinto, N.C., Castilho, R.F., Vercesi, A.E., Mitochondria and reactive oxygen species. Free Radic. Biol. Med. 47 (2009), 333–343.
32. Brookes, P.S., Yoon, Y., Robotham, J.L., Anders, M.W., Sheu, S.S., Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am. J. Physiol. Cell. Physiol. 287 (2004), C817–C833.
33. Adam-Vizi, V., Chinopoulos, C., Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol. Sci. 27 (2006), 639–645.
34. Cadenas, E., Mitochondrial free radical production and cell signaling. Mol. Asp. Med. 25 (2004), 17–26.
35. Hermes-Lima, M. Oxygen in biology and biochemistry: role of free radicals. In: Functional Metabolism: Regulation and Adaptation, Wiley-Liss, 2004, pp. 319–368.
36. Navarro, A., Mitochondrial enzyme activities as biochemical markers of aging. Mol. Asp. Med. 25 (2004), 37–48.
37. Cardoso, R.C., Lima, M.V.S., Chelesk, J., Peterson, E.J., Venâncio, T., Farrell, N.P., Carlos, R.M., Luminescent ruthenium complexes for theranostic applications. J. Med. Chem. 57 (2014), 4906–4915.
38. Vicentino, C., Constantin, J., Bracht, A., Yamamoto, N.S., Long-chain fatty acid uptake and oxidation in the perfused liver of Walker-256 tumour-bearing rats. Liver 22 (2002), 342–350.
39. Mizuno, M., Minato, K., Ito, H., Kawade, M., Terai, H., Tsuchida, H., Anti-tumor polysaccharide from the mycelium of liquid cultured Agaricus blazei mill. Biochem. Mol. Biol. Int. 47 (1999), 707–714.
40. Pfaffl, M.W., A new mathematical model for relative quantification in real-time RT-PCR. (7) Nucleic Acids Res., 29, 2001, 2002.
41. Chen, Y., Wang, M., Rosen, R.T., Ho, C.T., 1.1-Diphenyl-2-picrylhydrazyl radical-scavenging active components from Polygonum multiflorum thunb. J. Agric. Food Chem. 47 (1999), 2226–2228.
42. 2+ in the presence of xylenol orange. Comparison with the TBA assay and an iodometric method. Lipids 26 (1991), 853–856.
43. Aebi, H., Catalase in vitro. 1984, Academic Press, Orlando, 121–126.
44. Gao, R., Yuan, Z., Zhao, Z., Gao, X., Mechanism of pyrogallol autoxidation and determination of superoxide dismutase enzyme activity. Bioelectrochem. Bioenerg. 45 (1998), 41–45.
45. Habig, W.H., Papst, M.J., Jakoby, W.B., Glutathione S-transferases: the first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249 (1974), 7130–7139.
46. Sedlak, J., Lindsay, R.H., Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal. Biochem. 25 (1968), 192–205.
47. Bradford, M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72 (1976), 248–254.
48. Barakat, W., Elshazly, S.M., Mahmoud, A.A., Spirulinaplatensis lacks antitumor effect against solid ehrlich carcinoma in female mice. Adv. Pharmacol. Sci., 2015, 2015, 132873.
49. Gnaiger, E., Bioenergetics at low oxygen: dependence of respiration and phosphorylation on oxygen and adenosine diphosphate. Respir. Physiol. 128 (2001), 277–297.
50. Renner, K., Amberger, A., Konwalinka, G., Kofler, R., Gnaiger, E., Changes of mitochondrial respiration, mitochondrial content and cell size after induction of apoptosis in leukemia cells. Biochim. Biophys. Acta, 115–123, 1642, 2003.
51. Hutter, E., Unterluggauer, H., Garedew, A., Jansen-Durr, P., Gnaiger, E., High resolution respirometry – a modern tool in aging research. Exp. Gerontol. 41 (2006), 103–109.
52. Gnaiger, E., Capacity of oxidative phosphorylation in human skeletal muscle: new perspectives of mitochondrial physiology. Int. J. Biochem. Cell. Biol. 41 (2009), 1837–1845.
53. Scandurra, F.M., Gnaiger, E., Cell respiration under hypoxia: facts and artefacts in mitochondrial oxygen kinetics. Adv. Exp. Med. Biol. 662 (2010), 7–25.
54. Clarke, M.J., Bitler, S., Rennert, D., Buchbinder, M., Kelman, A.D., Reduction and subsequent binding of ruthenium ions catalyzed by subcellular components. J. Inorg. Biochem. 12 (1980), 79–87.
55. Novohradský, V., Bergamo, A., Cocchietto, M., Zajac, J., Brabec, V., Mestroni, G., Sava, G., Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity. Dalton Trans. 44 (2015), 1905–1913.
56. Jiang, M., Wei, Q., Wang, J., Du, Q., Yu, J., Zhang, L., Dong, Z., Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25 (2006), 4056–4066.
57. Dugbartey, G.J., Peppone, L.J., de Graaf, I.A., An integrative view of cisplatin-induced renal and cardiac toxicities: molecular mechanisms, current treatment challenges and potential protective measures. Toxicology 4 (2016), 58–66.
58. Mohanraj, M., Ayyannan, G., Raja, G., Jayabalakrishnan, C., Synthesis, spectral characterization, DNA interaction, radical scavenging and cytotoxicity studies ofruthenium(II) hydrazone complexes. J. Photochem. Photobiol. B. 158 (2016), 164–173.
59. Jeddi, F., Soozangar, N., Sadeghi, M.R., Somi, M.H., Samadi, N., Contradictory roles of Nrf2/Keap1 signaling pathway in cancer prevention/promotion and chemoresistance. DNA Repair 54 (2017), 13–21.
60. Milkovic, L., Zarkovic, N., Saso, L., Controversy about pharmacological modulation of Nrf2 for cancer therapy. Redox Biol. 12 (2017), 727–732.
61. Sharma, A.R., Gangrade, D.M., Bakshi, S.D., John, J.S., Ruthenium complexes: potential candidate for anti-tumour activity. Int. J. Chem. Tech. Res. 6 (2014), 828–837.
62. Harris, A.L., Hypoxia? A key regulatory factor in tumour growth. Nat. Rev. Cancer 2 (2002), 38–47.
63. Ferrara, N., Gerber, H.P., LeCouter, J., The biology of VEGF and its receptors. Nat. Med. 9 (2003), 669–676.
64. Chen, L., Endler, A., Shibasaki, F., Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors. Exp. Mol. Med. 41 (2009), 849–857.
65. Fischer, B., Heffeter, P., Kryeziu, K., Gille, L., Meier, S.M., Berger, W., Kowol, C.R., Keppler, B.K., Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation. Dalton Trans. 43 (2014), 1096–1104.
66. Bartel, C., Egger, A.E., Jakupec, M.A., Heffeter, P., Galanski, M., Berger, W., Keppler, B.K., Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019. J. Biol. Inorg. Chem. 16 (2011), 1205–1215.
67. A. Acco, A.L. Bastos-Pereira, A.A. Dreifuss, Characteristics and applications of the Walker-256 rat tumour. In: S.G. Pandalai, Daniel Pouliquen. (Org.). The rat in cancer research: a crucial tool for all aspects of translational studies, 1 ed., Trivandrum: Research Signpost/Transworld Research Network, 2012.
68. K V, A., Madhana, R.M., Kasala, E.R., Samudrala, P.K., Lahkar, M., Morin hydrate mitigates cisplatin-induced renal and hepatic injury by impeding oxidative/nitrosative stress and inflammation in mice. J. Biochem. Mol. Toxicol. 30 (2016), 571–579.
69. Lau, A.H., Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int. 56 (1999), 1295–1298.
70. Lieberthal, W., Triaca, V., Levine, J., Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am. J. Physiol. (Ren. Physiol.). 39 (1996), F700–F708.
71. Palipoch, S., Punsawad, C., Biochemical and histological study of rat liver and kidney injury induced by cisplatin. J. Toxicol. Pathol. 26 (2013), 293–299.
72. Danduga, R.C.R., Kumar, G.S., Kumar, K.P., Swamy, B.M.V., Kishore, K.V., Nephroprotective activity of Cissampelos pareira Linn. extract against cisplatin induced nephrotoxic rats. Am. J. Pharm. Tech. Res. 5 (2015), 480–488.
73. Mallick, A., More, P., Syed, M.M., Basu, S., Nanoparticle-mediated mitochondrial damage induces apoptosis in cancer. ACS Appl. Mater. Interfaces 1 (2016), 13218–13231.
74. Prabhu, V.V., Kannan, N., Guruvayoorappan, C., 1,2-Diazole prevents cisplatin-induced nephrotoxicity in experimental rats. Pharmacol. Rep. 65 (2013), 980–990.
75. Ognjanović, B.L., Djordjević, N.Z., Matić, M.M., Obradović, J.M., Mladenović, J.M., Stajn, A.Š., Saičić, Z.S., Lipid peroxidative damage on cisplatin exposure and alterations in antioxidant defense system in rat kidneys: a possible protective effect of selenium. Int. J. Mol. Sci. 13 (2012), 1790–1803.
76. Flocke, L.S., Trondl, R., Jakupec, M.A., Keppler, B.K., Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines. Invest. New Drugs 34 (2016), 261–268.
77. Mohanraj, M., Ayyannan, G., Raja, G., Jayabalakrishnan, C., Synthesis, spectral characterization, DNA interaction, radical scavenging and cytotoxicity studies ofruthenium(II) hydrazone complexes. J. Photochem. Photobiol. B 158 (2016), 164–173.
78. Camargo, C.A., da Silva, M.E., da Silva, R.A., Justo, G.Z., Gomes-Marcondes, M.C., Aoyama, H., Inhibition of tumor growth by quercetin with increase of survival and prevention of cachexia in Walker-256 tumor-bearing rats. Biochem. Biophys. Res. Commun. 25 (2011), 638–642.